Duncan Gregory Scott 4

What Happened
Duncan Gregory Scott, CEO of Dogwood Therapeutics, received a grant classified as an award/acquisition of 330,000 derivative shares on March 5, 2026. The reported acquisition price is $0.00, indicating a stock option or similar equity award rather than an open-market purchase. No cash was paid; this is a compensation award (derivative securities) that will vest over time per the filing.

Key Details

• Transaction date: 2026-03-05; Form 4 filed 2026-03-06 (timely filing).
• Transaction type/code: A (Grant/Award of derivative securities).
• Amount: 330,000 shares (derivative securities) at $0.00 reported price; total cash value at grant not reported on the Form 4.
• Vesting: Per footnote, the option vests one‑third on March 5, 2027, then 1/24th monthly thereafter.
• Shares owned after transaction: Not disclosed in this filing.
• No indication of exercise or sale — this is a grant, not a disposition.

Context
This appears to be a typical executive equity grant tied to future service and/or performance, not an immediate market purchase or sale. Because the award vests over time, the shares/options are not fully transferable or immediately liquid — such grants are common compensation and don't alone signal a near-term trading move.